Aims and MethodHealth promotion campaigns using current terminology have had limited success in reducing stigma to schizophrenia. Terminology and subgroups based on historical precedent, clinical experience and psychosocial research have been developed to provide an alternative to existing terminology, and the attitudes to schizophrenia and alternative terminology of a sample of medical students (n=241) were compared.ResultsOverall attitudes were significantly less negative with the alternatives. the students were less negative about the potential for recovery in relation to all the subgroups than for schizophrenia. Concerns about dangerousness were also less prominent with the exception of the drug-related group.Clinical ImplicationsSubgroups and alternative terminology should be further explored in programmes to destigmatise schizophrenia.
e14126 Background: Cytotoxic T lymphocyte-associated protein 4 (CTLA-4) is an inhibitory receptor that modulates T cell priming and CD28-dependent T cell activation. Modulation of this pathway by CTLA-4 antibodies has demonstrated clinical responses in patients with advance disease, however the mechanism of action of these antibodies remains controversial. It is currently understood that anti-CTLA-4 antibodies mediate antitumor effects through receptor-ligand blockade, and, in preclinical models, through depletion of intratumoral regulatory T (Treg) cells via an Fc-dependent mechanism. Recently, we reported a novel Fc-mediated contribution to T cell priming underscored the importance of Fc selection for optimal CTLA-4 antibody activity. AGEN1181 is a clinical stage Fc-engineered IgG1 antibody that leverages this novel mechanism for enhanced functionality. Methods: Fab-mediated biology of AGEN1181 was confirmed by assessing binding affinity, specificity, and blockade of CTLA-4:CD80/86 interactions. Fc-mediated functions of AGEN1181 were evaluated by FcγR binding, reporter-based FcγR signaling, and antibody-mediated Treg cell cytotoxicity assays. In vitro and in vivo pharmacology of AGEN1181 (alone or in combination with anti-PD-1) were evaluated in superantigen (staphylococcal enterotoxin)-mediated T cell stimulation assays and in a non-human primate (NHP) model. Safety and tolerability of AGEN1181 were assessed in cynomolgus monkeys administered 5 once-weekly intravenous bolus infusions at doses of 5, 30, or 100 mg/kg. Results: AGEN1181 bound to CTLA-4 with high affinity and specificity and demonstrated a range of enhanced functional activities relative to first-generation CTLA-4 antibodies. This included superior CD16 (FcγRIIIA) binding, Treg depletion and T cell priming (as measured by ZAP70 phosphorylation and interleukin-2 secretion). In NHP studies, a single dose of AGEN1181, alone or in combination with anti-PD-1 antibody upregulated Ki67 and ICOS expression on peripheral T cells. Finally, AGEN1181 exhibited an acceptable toxicologic profile in multi-dose NHP studies. Conclusions: AGEN1181, an Fc-engineered anti-CTLA-4 antibody exhibits a range of enhanced functional attributes relative to first-generation anti-CTLA-4 antibodies in preclinical studies. Phase 1 clinical studies for AGEN1181 will be initiated imminently.
Immune checkpoint blockade (ICB) of cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death receptor 1 (PD-1) have shown durable responses in cancer patients. However, responses have been limited to a small subset of patients, and resistance to ICB therapy continues to be a limiting factor to achieving broad and more durable clinical benefit. Considering the emerging hallmarks of response to ICB, we investigated how response to anti-PD-1 and anti-CTLA-4 therapy could be improved through antibody engineering and combination with other therapeutic approaches such as with novel immune checkpoint inhibitors (e.g. TIGIT, LAG-3), adoptive T cell therapy (ACT), cancer vaccines or focal radiation. In preclinical studies, we demonstrated that anti-CTLA-4 antibodies engineered to selectively enhance binding to human FcyRIIIA or mouse FcyRIV, respectively, significantly improve T cell effector function and tumor clearance in preclinical models that are known to have high immunogenicity and responsiveness to ICB single therapy such as MC-38 and CT-26. To identify novel T cell-intrinsic resistance mechanisms to current ICB therapies, we emulated a progressive anti-PD-1 refractory state in primary CD4- and CD8-positive NY-ESO-1 TCR-transduced T cells upon repeat co-culture with an antigen-expressing glioblastoma cell line. In this model, the addition of anti-CTLA-4, anti-LAG-3, or anti-TIGIT enhanced T cell cytotoxicity and killing of tumor target cells. Gene expression signatures associated with the anti-PD-1 refractory state in this system predicted anti-PD-1 response in melanoma patients. Combination therapy with anti-PD-1 was further validated in a PD-1 refractory mouse syngeneic tumor models demonstrating improved tumor control. Finally, to further address resistance mechanisms to ICB therapy, we evaluated the combination potential of anti-PD-1 and Fc-engineered anti-CTLA-4 with tumor targeted therapies in syngeneic tumor models such as B16 melanoma which are resistant to co-blockade of PD-1 and CTLA-4. In these studies, anti-PD-1 and Fc-engineered anti-CTLA-4, promoted significantly improved tumor control when combined together or with CD4 or CD8 ACT, low dose focal radiation (10 Gy), or an antigen-specific heat shock protein-based (HSC70) cancer vaccine as compared to either therapy alone. Our preclinical data suggest that the limited activity of anti-PD-1 can be addressed by combining with a Fc engineered anti-CTLA4 antibody or with select novel ICB. Furthermore, we have demonstrated that PD1-CTLA4 activity could be further improved when combined with conventional focal radiation or other immune-modulating targeted therapies such as ACT or vaccines to significantly enhance tumor antigenicity and overcome resistance to conventional ICB. Citation Format: Antoine J. Tanne, Sylvia Vincent, Benjamin Duckless, Elena Paltrinieri, Simarjot Pabla, Andrew Basinski, Sudesh Pawaria, Vidur Patel, Margaret Wilkens, Bishnu Joshi, Matthew Hancock, Daniel Levey, Thomas Horn, Cailin Joyce, David Savitsky, Cori Gorman, Jennifer Buell, Dhan Chand. Expanding the therapeutic potential of anti-PD-1 and anti-CTLA-4 therapy with innovative Fc engineering and rationale combinations for the treatment of solid tumors [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 922.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.